JNJ vs. MOH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at JNJ and MOH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | JNJ | MOH |
|---|---|---|
| Company Name | Johnson & Johnson | Molina Healthcare, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Health Care Providers & Services |
| Market Capitalization | 454.31 billion USD | 10.95 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | January 2, 1962 | July 2, 2003 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of JNJ and MOH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | JNJ | MOH |
|---|---|---|
| 5-Day Price Return | 3.87% | 4.67% |
| 13-Week Price Return | 20.92% | -15.70% |
| 26-Week Price Return | 13.75% | -38.68% |
| 52-Week Price Return | 17.04% | -39.13% |
| Month-to-Date Return | 1.74% | 5.54% |
| Year-to-Date Return | 30.44% | -30.61% |
| 10-Day Avg. Volume | 8.90M | 1.03M |
| 3-Month Avg. Volume | 8.47M | 1.35M |
| 3-Month Volatility | 18.23% | 55.31% |
| Beta | 0.35 | 0.52 |
Profitability
Return on Equity (TTM)
JNJ
30.39%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
In the upper quartile for the Pharmaceuticals industry, JNJ’s Return on Equity of 30.39% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
MOH
24.86%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
In the upper quartile for the Health Care Providers & Services industry, MOH’s Return on Equity of 24.86% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
JNJ
25.00%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
A Net Profit Margin of 25.00% places JNJ in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
MOH
2.60%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
MOH’s Net Profit Margin of 2.60% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
JNJ
30.18%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
An Operating Profit Margin of 30.18% places JNJ in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
MOH
3.81%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
MOH’s Operating Profit Margin of 3.81% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | JNJ | MOH |
|---|---|---|
| Return on Equity (TTM) | 30.39% | 24.86% |
| Return on Assets (TTM) | 12.16% | 7.06% |
| Net Profit Margin (TTM) | 25.00% | 2.60% |
| Operating Profit Margin (TTM) | 30.18% | 3.81% |
| Gross Profit Margin (TTM) | 67.98% | 14.88% |
Financial Strength
Current Ratio (MRQ)
JNJ
1.01
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
JNJ’s Current Ratio of 1.01 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
MOH
1.66
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
MOH’s Current Ratio of 1.66 is in the upper quartile for the Health Care Providers & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
JNJ
0.65
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
JNJ’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MOH
0.77
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
MOH’s Debt-to-Equity Ratio of 0.77 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
JNJ
34.01
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
JNJ’s Interest Coverage Ratio of 34.01 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
MOH
14.47
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
MOH’s Interest Coverage Ratio of 14.47 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | JNJ | MOH |
|---|---|---|
| Current Ratio (MRQ) | 1.01 | 1.66 |
| Quick Ratio (MRQ) | 0.68 | 1.61 |
| Debt-to-Equity Ratio (MRQ) | 0.65 | 0.77 |
| Interest Coverage Ratio (TTM) | 34.01 | 14.47 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
JNJ
2.65%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
JNJ’s Dividend Yield of 2.65% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
MOH
0.00%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
MOH currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
JNJ
53.34%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
JNJ’s Dividend Payout Ratio of 53.34% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
MOH
0.00%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
MOH has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | JNJ | MOH |
|---|---|---|
| Dividend Yield (TTM) | 2.65% | 0.00% |
| Dividend Payout Ratio (TTM) | 53.34% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
JNJ
20.10
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
JNJ’s P/E Ratio of 20.10 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
MOH
9.47
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
In the lower quartile for the Health Care Providers & Services industry, MOH’s P/E Ratio of 9.47 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
JNJ
5.03
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
JNJ’s P/S Ratio of 5.03 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
MOH
0.25
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
In the lower quartile for the Health Care Providers & Services industry, MOH’s P/S Ratio of 0.25 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
JNJ
4.68
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
JNJ’s P/B Ratio of 4.68 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
MOH
3.51
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
MOH’s P/B Ratio of 3.51 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | JNJ | MOH |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 20.10 | 9.47 |
| Price-to-Sales Ratio (TTM) | 5.03 | 0.25 |
| Price-to-Book Ratio (MRQ) | 4.68 | 3.51 |
| Price-to-Free Cash Flow Ratio (TTM) | 24.56 | 10.64 |